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Purpose: Racial differences exist in the incidence of prostate cancer (PCa). Although many studies have looked at the performance 
of prostate-specific antigen (PSA) and PSA density (PSAD) in the detection of PCa, only a few have looked at it in relation to Indonesian 
men. The objective of this study is to find out better PSA and PSAD cutoff point in the detection of PCa in Indonesian men.
Methods: A total of 404 consecutive Indonesian men underwent prostate biopsy for suspicion of PCa from 2008 to 2011. The biopsy 
criteria include one or more of the following: serum PSA more than 10 ng/mL, PSAD more than 0.15 if PSA 4–10 ng/mL, hypoechoic 
lesion during transrectal sonography and/or abnormal digital rectal examination. 
Results: Forty five out of 404 (11.1%) had positive biopsies. The mean age, prostate volume, PSA and PSAD were respectively 64.06 
years, 43.03 mL, 45.59 ng/mL and 1.15. Of the 404, 131 cases (32.4%) were confirmed to be urinary retention. Positive urine culture 
found in 182 cases (45%). The cutoff point to detect PCa as estimated by the receiver operating characteristics was 6.95 ng/mL for 
PSA (sensitivity 97.8%, specificity 19.6%) and 0.7072 for PSAD (sensitivity 62.2%, specificity 78.7%). Positive predictive value for this 
PSA and PSAD cutoff point were 11.6% and 27.5% respectively (P=0.004 and P=0.000). There was a significant correlation between 
hypoechoic lesion and positive biopsy results (P=0.000). Urinary retention elevates PSA cutoff point to 14.55 (sensitivity 90.9%, 
specificity 50%), while positive urine culture alters almost no PSA cutoff elevation. 
Conclusions: PSA and PSAD cutoff point for Indonesian men in this series is relatively different from international consensus. 
Furthermore, these data show that PSA and PSAD cutoff point must be adjusted to racial variation to discriminate between malignant 
and benign disease. Urinary retention is a significant factor for PSA cutoff increase.
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INTRODUCTION
Prostate cancer (PCa) is the most common estimated cancer 
among men. It is responsible for approximately 33% of inci-
dental cases in men [1]. Despite its prevalence, the natural 
history of this disease is remarkably heterogeneous [2]. Regu-
lar serum prostate-specific antigen (PSA) evaluation and digi-
tal rectal examination (DRE) are recommended for detecting 
PCa [1]. The serum PSA level is among the best of the screen-
ing tools available in medicine today and is recognized as the 
best marker for early detection [3]. PSA testing is widely used 
for PCa screening and increases cancer detection by 81% over 
use of the DRE alone. Nearly 70% of cancers can be detected 
using PSA cutoff 4 ng/mL in the first 4 years of screening. 
However, PSA is limited by its relative lack of specificity when 
serum concentrations are moderately elevated (4–10 ng/mL). 
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The choice of a PSA threshold or cut point above which one 
would recommend further evaluation with prostate biopsy to 
rule out PCa is controversial. Although the PSA threshold of 
4 ng/mL has been the most commonly used, the value that 
most efficiently balances the dual goal of reducing cancer 
mortality and reducing unnecessary testing is unknown [4].
 Recently, various strategies were introduced to improve 
the sensitivity and specificity of the PSA. Among those, we 
can highlight PSA density (PSAD), PSA velocity (PSAV), 
distribution of serum PSA levels according to age and the 
determination of molecular forms of PSA [5]. Because of the 
increasing frequency of benign prostate hyperplasia (BPH) 
and consequent prostate growth from 40 years on, some ad-
ditional parameters were proposed in association with PSA. 
One of these parameters is PSAD with cutoff level of 0.15, for 
patients with PSA between 4–10 ng/mL, would discriminate 
most of the cases of carcinoma from BPH. But, other studies 
show that PSAD has no value for such discrimination [6]. The 
specific cutoff for PSA and PSAD to delineate patients at high 
risk who should undergo biopsy has been controversial, espe-
cially when the PSA and PSAD values are influenced by race 
and environment [7]. In the Western world, the reliable cutoff 
value of PSA to perform prostatic biopsies is still in debate: a 
PSA level more than 4.0 ng/mL was stated as abnormal and 
it is recommended to perform prostatic biopsies, but present 
studies reported that a cutoff point below 4 ng/mL would also 
produce a high positive predictive value (PPV) [8]. While in 
Asia, with its low rate of PCa, some authors revealed a higher 
cutoff of PSA and PSAD to detect PCa. Therefore, minimizing 
unnecessary biopsies might be a more important issue than 
maximizing the cancer detection rate [9]. In 2000, Rahardjo et 
al. [10] studied 805 consecutive patients and revealed higher 
PSA and PSAD cutoffs (8 ng/mL and 0.20 ng/mL) in Indone-
sian men. They also found that 148 biopsies (33.4%) could be 
saved with this cutoff level.
MATERIALS AND METHODS
The study was performed in an outpatient public reference 
urology service for prostatic diseases. Demographic data, co-
morbidities, urine culture, urinary retention, PSA, founding 
during transrectal ultrasonography (TRUS), pathologic data 
as well as clinical information from 404 patients who under-
went prostate biopsy for PCa screening at the Department of 
Urology, University of Airlangga, Indonesia, during 2008 to 
2011 were entered in a retrospective database.
 The biopsy criteria include one or more of the following: 
PSA greater than 10 ng/mL; PSAD greater than 0.15 (in PSA 
4–10 ng/mL); hypoechoic lesion during TRUS and/or; ab-
normal DRE. Prostate volume was measured through TRUS. 
The specimen of the biopsy were fixed in 10% formalin and 
submitted to pathological department for hematoxylin-eosin 
staining. The findings were classified as adenocarcinoma 
or nodular hyperplasia. Histopathological studies were per-
formed by the same pathologist. PSA determination was car-
ried out by the Immulite assay (Diagnostics Products Co., Los 
Angeles, CA, USA). TRUS guided systematic 10-core biopsy 
was performed using a biplanar technique with a 7.5 MHz 
probe (Hitachi EUB 405, Hitachi Medical Co., Tokyo, Japan).
 For statistical analysis, the IBM SPSS ver. 10.0.1 (IBM Co., 
Armonk, NY, USA) was used. Since all continuous variables 
did not present a normal distribution, Mann-Whitney U and 
the Kruskal-Wallis tests was applied to compare the groups’ 
median. Correlation among variables was analyzed with chi-
square test. 
 The statistical program Medcalc ver. 8.1.0.0 (Medcalc Soft-
ware, Ostend, Belgium) was used to demonstrate the best 
cutoff point for each diagnosis test as well as to calculate its 
respective PPVs, negative predictive values (NPVs), sensitivi-
ties and specificities to predict PCa. The receiver operating 
characteristics (ROC) curve was employed to graphically 
demonstrate the sensitivities and specificities of the different 
diagnostic tests. All statistical analysis was performed con-
sidering P<0.05 statistically significant and with a 95% confi-
dence interval (CI).
RESULTS
Four hundred and four patients were finally included in the 
study. All were included according to data availability from 
the medical records. A summary of patient characteristics is 
presented in Table 1. Mean age was 64.06±7.5 years (range, 
34 to 84 years). Mean PSA was 45.59 ng/mL (range, 0.4 to 
1,400 ng/mL). Mean prostate volume and PSAD were 43.03 
and 1.15 respectively. Of the 404, 131 cases (32.4%) were con-
firmed to be urinary retention and were catheterized. PSA for 
retention case were examined at least 5 days after catheter-
ization. Positive urine culture was found in 182 cases (45%). 
Hypoechoic lesion during TRUS was found in 88 cases (22%). 
Regarding baseline PSA, 2.5% of patients presented with 
PSA<2.5 ng/mL, 1.7% between 2.5–4 ng/mL, 26.2% between 
4.1–10 ng/mL and 69.6% with PSA more than 10 ng/mL. Over-
all detection of PCa was 11.1% (45 cases). The remaining 359 
cases had benign lesions comprising BPH. Twenty nine out of 
these 45 PCa had nodule from DRE.
 The discriminating power to detect PCa as estimated by the 
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ROC curve was 0.778 for PSA and 0.734 for PSAD. Estimates 
for sensitivity, specificity and predictive values for different 
PSA and PSAD cutoff points are shown in Fig. 1. The opera-
tion characteristics of both tests at maximum discrimination 
cutoffs were computed. This was 6.95 ng/mL for PSA and 
0.7072 for PSAD. For PSA cutoff point of 6.95 ng/mL, the 
sensitivity was 97.8%, specificity 19.6%, PPV 13.5%, and NPV 
98.6%. While for PSAD cutoff point of 0.7072, the sensitivity 
was 62%, specificity 78.7% and PPV 27.5% (Table 2). There 
was a significant correlation between cutoff PSA and adeno-
carcinoma (P=0.004) as well as between cutoff PSAD and 
pathology result (P=0.000) as shown in Table 3.
 In urinary retention group, ROC curve analysis revealed 
two fold PSA cutoff increase (14.55 ng/mL) with discriminat-
ing power 0.890 (area under curve [AUC], 0.89; 95% CI, 0.803 
to 0.977; P=0.000) (Fig. 2A). Sensitivity and specificity was 
90.9% and 50% respectively. While for positive urine culture 
group, ROC curve analysis revealed almost no PSA cutoff in-
crease (7.065 ng/mL) with discriminating power 0.890 (AUC, 
0.783; 95% CI, 0.693 to 0.873; P=0.000) (Fig. 2B). Sensitivity 
and specificity was 96.9% and 20% respectively.
 Using cross tabulation, there was a significant correlation 
between hypoechoic area and adenocarcinoma (P=0.000) 
as shown in Table 4. Statistical calculation revealed higher 
PCa incidence in hypoechoic area group (22.7%) compared 
to only 8% in without lesion group. PPV and NPV were 22.7% 
and 92% respectively.
 The Gleason score (GS) group for PSA greater than 6.95 
ng/mL was 81.4% for moderate and 16.3% for high grade. All 
patients with PSA less than 6.95 ng/mL shows moderate GS. 
Cross tabulation shows no significant correlation between 
Table 1. Characteristics of 404 patients underwent prostate bi-
opsy
Variable No. Value
Mean age (yr) 385 64.06
Prostate specific antigen 397 45.59 (0.4–1,400)
Mean PSAD 392 1.15
Mean prostate volume 398 43.03
Retention 404
No 273 (67.6)
Yes 131 (32.4)
Digital rectal examination 404
No nodule 375 (92.3)
Nodule 29 (7.7)
Hypoechoic area 400
No 312 (78)
Yes 88 (22)
Bladder stone 404
No 393 (97.3)
Yes 11 (2.7)
Pathology 404
Nodular hyperplasia 359 (88.9)
Adenocarcinoma 45 (11.1)
Urine culture 404
Negative 222 (55)
Positive 182 (45)
Gleason score (sum)
0 359 (89.1)
3 1 (0.2)
4 2 (0.5)
5 12 (3)
6 6 (1.5)
7 16 (4)
9 7 (1.7)
Values are presented as mean (range) or number (%).
PSAD, prostate-specific antigen density.
Fig. 1. Receiver operating characteristics (ROC) curve depicting diagnostic accuracy of prostate-specific antigen (PSA) (A) and diag-
nostic accuracy of PSA density (B). The ROC curve shows perpendicular height above the diagonal and wide area under the curve in-
dicating that it is an accurate test. 
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PSA cutoff point and GS (P=0.893). Among those with PSAD 
>0.7072, 88.9% were categorized as moderate GS and 7.4% 
as high-grade GS. Meanwhile, among pastients with PSAD 
<0.7072, moderate and high grade GS was 70.6% and 29.4%, 
respectively. Statistical calculation using cross tabulation 
shows no significant correlation between PSAD cutoff point 
and GS (P=0.121) as shown in Table 5. 
DISCUSSION
In United States, PCa has been the common noncutaneous 
malignancy in men since 1984, now accounting for one quar-
ter of all such cancers. The estimated lifetime risk of disease 
is 16.72%, with a lifetime risk of death at 2.57%. Its incidence 
varies widely between countries and ethnic populations, with 
disease rates differing by more than 100-fold. Although the 
Table 2. Performance of both cutoff levels
PSA (%) PSAD (%)
Cutoff 6.95 0.71
Sensitivity 97.8 62.2
Specificity 19.6 78.7
Positive predictive value 13.5 27.5
Negative predictive value 98.6 94.1
PSA, prostate-specific antigen; PSAD, PSA density.
Table 3. Cross tabulation of PSA and PSAD diagnostic cutoff 
points for prostate cancer detection 
Category 
Pathology
Total
Adeno Ca No
≥Cutoff
PSA 44 (13.5) 283 (86.5) 327 (100)
PSAD 28 (27.5) 74 (72.5) 102 (100)
≤Cutoff
PSA 1 (1.4) 69 (98.6) 70 (100)
PSAD 17 (5.9) 273 (94.1) 290 (100)
Total
PSA 45 (11.3) 347 (88.5) 397 (100)
PSAD 45 (11.5) 347 (88.5) 392 (100)
Values are presented as number (%). 
PSA, prostate-specific antigen; PSAD, PSA density.
Table 4. Cross tabulation of hypoechoic lesion for prostate can-
cer detection 
Hypoechoic lesion
Pathology
Total
Adeno Ca No
Yes 20 (22.7) 68 (77.3) 88 (100)
No 25 (8.0) 287 (92.0) 312 (100)
Total 45 (11.3) 355 (88.8) 400 (100)
Values are presented as number (%). 
Table 5. Cross tabulation of PSA and PSAD diagnostic cutoff 
points with Gleason score 
Category
Gleason score
Total
Mild Moderate High
≤Cutoff
PSA 0 (0) 1 (100) 0 (0) 1 (100)
PSAD 0 (0) 12 (70.6) 5 (29.4) 17 (100)
≥Cutoff
PSA 1 (2.3) 35 (81.4) 7 (16.3) 43 (100)
PSAD 1 (3.7) 24 (88.9) 2 (7.4) 27 (100)
Total
PSA 1 (2.3) 36 (81.8) 7 (15.9) 44 (100)
PSAD 1 (2.3) 36 (81.8) 7 (15.9) 44 (100)
Values are presented as number (%). 
 PSA, prostate-specific antigen; PSAD, PSA density.
Fig. 2. Receiver operating characteristics (ROC) curve shows area under curve for prostate-specific antigen (PSA) cutoff point in uri-
nary retention group (A) and positive urine culture group (B).
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specific causes of PCa initiation and progression are not yet 
known, considerable evidence suggests that both genetic and 
environment play a role in the origin and evolution of this 
disease [11].
 Almost all cases of PCa are adenocarcinoma. About 4% 
of PCa cases exhibit transitional cell morphology and are 
believed to have developed from the urogenital lining of the 
prostatic urethra [12]. Today, PSA-based screening of a symp-
tomatic men has led to the adaptation of TRUS biopsy as the 
standard of care for routine prostate biopsy. Currently, most 
clinicians recommend biopsy once a patient’s serum PSA 
rises above 4.0 ng/mL, although significant research efforts 
are ongoing to identify the optimal PSA threshold to recom-
mend prostate biopsy in the asymptomatic patient. Evidence 
to lower the PSA threshold from work by Catalona’s group 
showed higher rates of organ-confined disease at the time of 
radical retropubic prostatectomy in samples from PSAs in the 
2.6–4.0 ng/mL range. These findings have led many urologists 
to now recommend prostate biopsy to men younger than 60 
years of age once their PSA level rises above 2.5 ng/mL. Re-
gardless of initial PSA value, a PSAV greater than 0.75 ng/mL/
yr is frequently associated with PCa and warrants biopsy [11].
 Although numerous grading systems exist for the evalua-
tion of prostatic adenocarcinoma, the GS system is the most 
widely accepted. The GS is based on the glandular pattern of 
the tumor as identified at relatively low magnification, both 
the primary (predominant) and the secondary (second most 
prevalent) architectural patterns [7]. One point needs to be 
clarified is that the primary Gleason grade is perhaps the 
most important with respect to placing patients in prognostic 
groups [13].
 Serum PSA above 4 ng/mL with or without an abnormal 
DRE is generally accepted as an indication for needle biopsy 
of the prostate [14]. Disruption of the normal prostatic ar-
chitecture, such as by prostatic disease, inflammation, or 
trauma, allows greater amounts of PSA to enter the general 
circulation [2]. PSA was initially introduced for postoperative 
follow-up and was gradually used as a screening test, which 
brought about tremendous change in the morbidity and mor-
tality of PCa [3].
 The PSAD parameter was developed to undermine the 
influence of the prostate volume on the serum level of PSA 
[6]. Meanwhile, PSAD greater than 0.15 is associated with 
25% incidence of cancer, and a PSAD less than 0.10 with 5% 
incidence of cancer [7]. Two studies performed to determine 
the reference values of serum PSA for Iranian men revealed 
that the PSA values were significantly lower than those for 
white and black Western men, and slightly lower than those 
for Japanese men [7]. Black men are at 60% increased risk for 
PCa and at 150% increased risk for PCa mortality. In contrast, 
Asian/Pacific Islander American men are at an overall 40% 
age adjusted lower risk for PCa and at 55% lower risk for PCa 
mortality than white men [15].
 Catalona et al. [16] reported that a PSA level of 4 ng/mL or 
higher was appropriate as the PSA cutoff value for the screen-
ing of PCa. Since then, this value has been most commonly 
used clinically; whereas its sensitivity is 67.5% to 80% and the 
specificity is only 20% to 30%. When total PSA cutoff level is 
considered high, some clinically important cancers may be 
overlooked. In contrast, when it is considered low, unneces-
sary biopsies would increase morbidity and cost. However, 
approximately 20% of PCa patients have serum total PSA lev-
els below 4 ng/mL. In some studies, PCa detection rate was 
between 2% to 28% in patients who had PSA less than 4.0 ng/
mL. Thus, patient selection, core number, core localization, 
and the suitable rebiopsy time are still controversial issues [1].
 Colberg et al. [17] reported that PCa detection rate was 
7.2% in 121 volunteers with suspicious DRE and/or TRUS and 
serum total PSA level between 2.9–4.0 ng/mL. In a study by 
Babaian et al, [18] 151 volunteers had serum total PSA value 
between 2.5–4.0 ng/mL, and PCa was found in 24.5% cases. 
Another study evaluated 883 patients with serum total PSA 
level between 2.0–3.9 ng/mL, and PCa rate was 14.3%. Clini-
cally important cancers, 20% of which were beyond prostate, 
were reported in 89% of the patients with serum total PSA 
level less than 4.0 ng/mL [1]. Wu and Huang [9] in 2004 found 
that 162 biopsies (13.1%) might be avoided for Chinese popu-
lation if the PSA cutoff was 6.0 ng/mL but 4 cancers (1.6%) 
would have been overlooked.
 A cross-sectional study involving 805 patients from 40 to 
95 years by Mochtar et al. [19] in Jakarta-Indonesia found 105 
and 303 unnecessary prostate biopsies for intermediate and 
high PSA level, subsequently. Among 805 patients, only 35 pa-
tients had histologically confirmed PCa, i.e., 3 of 108 patients 
with PSA 4–10 ng/mL and PSAD >0.15, and 32 of 335 patients 
with PSA >10 ng/mL. With a PSA cutoff level of ≥8 ng/mL, 
they found 100% sensitivity to PCa. PSAD ≥0.20 within a PSA 
level of 8–30 ng/mL gave 100% sensitivity to prostate cancer. 
Using these new cutoffs there would be 148 biopsies (33.4%) 
saved. Unfortunately, therefore, they concluded that the com-
monly accepted values of serum PSA level and PSAD resulted 
in many unnecessary biopsies in Indonesian patients [10]. 
Unfortunately, they did not discuss urinary retention and the 
possibility of urinary tract infection that may alter this cutoff 
value as almost half of Indonesian BPH patients came to seek 
medical helps after urinary retention.
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 In our study, we defined PSA 6.95 ng/mL as the best cutoff 
point to detect PCa (sensitivity 97.8%, specificity 42.2%, PPV 
13.5%). We also found that this cutoff has a significant cor-
relation with pathology result (P=0.004). Compared with 
several prior studies using cutoff PSA 4 ng/mL; the sensitiv-
ity, specificity and rate of misdiagnostic are almost the same. 
Since Indonesia has low rate of PCa and previous study shows 
only 2.8% PCa detection rate in intermediate PSA range (4–10 
ng/mL) with PSAD>0.15, this lead to presumption that for 
PSA less than 4 ng/mL the incidense rate must be much 
lower. Consequently, biopsy for PSA less than 4 ng/mL is not 
mandatory and recommended only for specific cases. This is 
intended to reduce morbidity and avoid unnecessary biopsies.
 In patients with serum PSA more than 10 ng/mL, applying 
PSAD of 0.15 will increase the specificity and PPV of the test 
without significantly compromising the test sensitivity. In ad-
dition, it seems reasonable that all men with PSA greater than 
4 ng/mL should have a TRUS biopsy if their PSAD is greater 
than 0.15 [7]. In general, the detection rates of PCa based on 
the PSA level are 10–20% at 2.5–4.0 ng/mL; 25% at 4.1–10.0 
ng/mL; and 50–60% at 10 ng/mL or higher [3]. Sheikh et al. 
[14] found PSAD cutoff point 0.32 in Kuwaiti people has a 
specificity of 80%, suggesting that it can be used as a confir-
matory but not an exclusionary test. A retrospective study of 
132 uncatheterized BPH and PCa cases in Jakarta-Indonesia 
by Mochtar et al. [19] revealed an optimum PSAD cutoff level 
of 0.19. At this level, the measured sensitivity was 100% with 
a specificity of 79%. From statistical analysis using ROC, we 
also found 0.7072 as the best PSAD cutoff in Indonesian men 
(relatively in this series). Sensitivity, specificity, and PPV was 
62%, 78.7% and, 27.5%, respectively. There was also a signifi-
cant correlation between cutoff PSAD and pathology result 
(P=0.000). This high cutoff is equivalent with high mean 
PSAD (1.15). In contrast to literature study, this Indonesian 
men (Asian) shows high PSA and PSAD.
 Total PSA can be reduced by certain treatments such as 
5-α reductase inhibitors and may be increased in acute urine 
retention, during the 48 hours after ejaculation, in prostate 
biopsies or placement of a urinary catheter, transurethral 
resection of the prostate, BPH and prostatitis [20]. In our 
study, positive urine culture alters almost no PSA increase 
(from 6.95 to 7.065) and it is contrary to previous studies. This 
slight increase phenomenon may occur because we did not 
separate symptomatic and asymptomatic group. Therefore, 
positive urine culture could not describe the urinary tract 
infection or prostate inflammatory status. Consequently, we 
recommend the same PSA cutoff (6.95 ng/mL) as the best 
level to detect PCa.
 Elevation of PSA can also be found in urinary retention. In 
2003, Chawla et al. [21] reported significant PSA elevation in 
patients urinary retention. Among the 74 BPH patients with 
urinary retention, 42 (56.8%) has elevated PSA; 8 (10.8%) of 
these patients even showed PSA concentrations above 25 ng/
mL. While in no-retention subgroup, only 11 out of 38 (28.9%) 
had above normal PSA concentrations and none of these had 
PSA more than 25 ng/mL. The effect of urinary retention in 
PSA elevations was further confirmed by significantly high 
odds ratio of 3.22 (95% CI, 1.29 to 8.15). Erdogan et al. [20] 
randomly divided 35 BPH patients into 2 groups, urethral 
catheterization and suprapubic cystostomy. He found that 
PSA level significantly increased 2 hours, 12 hours and 7 days 
after catheterization (P<0.05) but not in cyctostomy group. 
Lipsky et al. [22] studied 1,492 consecutive BPH patients and 
reported that overall PSA in catheterized patients was twice 
as high compared to patients without catheter. In contrast 
to positive urine culture group, urinary retention made a big 
impact on PSA cutoff level. We found that urinary retention 
could double PSA cutoff to 14.55 ng/mL with sensitifity 90.9% 
and specificity 50%. 
 Despite the higher prevalence of cancers discovered in 
prostates with hypoechoic areas, Onur et al. [23] found that 
hypoechoic lesion itself was not associated with increased 
cancer prevalence compared with biopsy cores from isoecho-
ic areas in a contemporary series of almost 4,000 patients. 
While Gosselaar et al. [24] found PCa detected from directed 
hypoechoic lesion biopsy was limited to only 3.5% of the 
1,840 men. In this series, we found significant correlation be-
tween hypoechoic lesion and PCa (PPV 22.7% and NPV 92%).
Lotfi et al. [7] in 2009 found 80% of the cancers diagnosed in 
102 patients were in the mid or high-grade range of GS. From 
multivariate analysis, they also failed to prove correlation 
among PSA, PSAD and GS [7]. While Hofner et al. [25] in 2010 
found only minor relationship between PSAD and final GS 
(R2=0.33, P=0.001). In this series, we found no significant 
correlation between new PSA cutoff value and GS, as well as 
new PSAD cutoff value with GS. 
 An important limitation of our study is the retrospective de-
sign. Another drawback is the calculation of PSAD based on 
transrectal ultrasound. Though TRUS volume measurements 
correlate with pathological prostate volumes, they do not 
represent the exact values, but underestimate true prostate 
volumes in most cases. Nevertheless, interobserver reliability 
of transrectal volume measurements is high. Bias could also 
be introduced by different TRUS biopsy operator. Since PSA 
<4 ng/mL and or intermediate PSA with PSAD <0.15 were 
not included in biopsy criteria, this can lead to differences in 
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statistical assessment. Acute urinary retention and positive 
urine culture could also make a bias value, therefore PSA test 
was examined at least 5 days after acute urinary retention 
and catheterization, and repeat PSA test in cases with a high 
results. Obviously, it will be essential to prove our concept of 
new PSA and PSAD cutoff value in larger series; thereby, the 
exact lower cutoff value could be refined. 
 In conclusion, PSA and PSAD cutoff point for Indonesian 
men in this series is relatively different from international 
consensus. The difference might be caused by racial variation 
of either prostate volume. Furthermore, these data show that 
PSA and PSAD cutoff point must be adjusted to racial varia-
tion to discriminate between malignant and benign disease. 
Urinary retention is a significant factor for PSA cutoff increase. 
CONFLICT OF INTEREST
No potential conflict of interest relevant to this article was re-
ported.
REFERENCES
1. Aslan Y, Tekdogan, Tuncel A, Uzun MB, Karabulut E, Atan A. 
Serum dehydroepiandrosterone sulfate usage for early detec-
tion of prostate cancer in men with serum prostate specific 
antigen level between 2.5 and 4.0 ng/mL: a pilot study. Turk J 
Med Sci 2008;38:399-404.
2. Carrol P, Albertsen PC, Greene K, Babaian, RJ, Carter HB, 
Gann PH, et al., editors. Prostate-specific antigen best prac-
tice statement: 2009 update. Linthicum; American Urological 
Association Education and Research Inc.; 2009.
3. Kim HW, Ko YH, Kang SH, Lee JG. Predictive factors for 
prostate cancer in biopsy of patients with prostate-specific 
antigen levels equal to or less than 4 ng/ml. Korean J Urol 
2011;52:166-71.
4. Reis LO, Zani EL, Alonso JC, Simoes FA, Rejowski RF, Ferreira 
U. Does the criterion for prostate biopsy indication impact its 
accuracy? A prospective population-based outpatient clini-
cal setting study. Actas Urol Esp 2011;35:10-4.
5. Gregorio EP, Grando JP, Saqueti EE, Almeida SH, Moreira 
HA, Rodrigues MA. Comparison between PSA density, free 
PSA percentage and PSA density in the transition zone in the 
detection of prostate cancer in patients with serum PSA be-
tween 4 and 10 ng/mL. Int Braz J Urol 2007;33:151-60.
6. Martins ACP, Borelli- Bovo TJ, Reis RB, Paschoalin EL, Cologna 
AJ, Suaid HJ. Performance Of PSA and of PSA density in the 
diagnosis of prostate carcinoma. Acta Cir Bras 2002;17:7-11.
7. Lotfi M, Assadsangabi R, Shirazi M, Jali R, Assadsangabi A, 
Nabavizadeh SA. Diagnostic value of prostate specific anti-
gen and its density in Iranian men with prostate cancer. Iran 
Red Crescent Med J 2009;11:170-5.
8. Gilbert SM, Cavallo CB, Kahane H, Lowe FC. Evidence sug-
gesting PSA cutpoint of 2.5 ng/mL for prompting prostate 
biopsy: review of 36,316 biopsies. Urology 2005;65:549-53.
9. Wu TT, Huang JK. The clinical usefulness of prostate-specific 
antigen (PSA) level and age-specific PSA reference ranges for 
detecting prostate cancer in Chinese. Urol Int 2004;72:208-11.
10. Rahardjo D, Kamil ST, Pakasi LS. Rationale for using serum 
prostate-specific antigen (PSA) level and PSA density (PSAD) 
to detect prostatic malignancy in a country with low pros-
tate cancer incidence. Gan To Kagaku Ryoho 2000;27 Suppl 
2:563-70.
11. Loeb S, Carter HB. Early detection, diagnosis, and staging of 
prostate cancer. In: Wein AJ, Kavoussi LR, Novick AC, Partin 
AW, Peters CA, editors. Campbell-Walsh urology. 10th ed. 
Philadelphia: Elsevier; 2012. p. 2763-70.
12. Crawford ED. Understanding the epidemiology, natural his-
tory, and key pathways involved in prostate cancer. Urology 
2009;73:S4-10. 
13. Presti JC, Kane CJ, Shinohara K, Carroll PR. Neoplasm of the 
prostate gland. In: Tanagho EA, McAninch JW. Smith’s gen-
eral urology. 17th ed. Columbus: McGraw-Hill Co.; 2008. p. 
348-74.
14. Sheikh M, Al-Saeed O, Kehinde EO, Sinan T, Anim JT, Ali Y. 
Utility of volume adjusted prostate specific antigen density 
in the diagnosis of prostate cancer in Arab men. Int Urol 
Nephrol 2005;37:721-6.
15. Elliott CS, Shinghal R, Presti JC Jr. Racial variations in the 
performance of prostate specific antigen and prostate spe-
cific antigen density in the era of extended prostate biopsy 
schemes. J Urol 2008;180:1318-23.
16. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of or-
gan-confined prostate cancer is increased through prostate-
specific antigen-based screening. JAMA 1993;270:948-54.
17. Colberg JW, Smith DS, Catalona WJ. Prevalence and patho-
logical extent of prostate cancer in men with prostate specific 
antigen levels of 2.9 to 4.0 ng/ml. J Urol 1993;149:507-9.
18. Babaian RJ, Johnston DA, Naccarato W, Ayala A, Bhadkam-
kar VA, Fritsche HH Jr. The incidence of prostate cancer in a 
screening population with a serum prostate specific antigen 
between 2.5 and 4.0 ng/ml: relation to biopsy strategy. J Urol 
2001;165:757-60.
19. Mochtar CA, Rahardjo D, Umbas R. A higher PSA-density 
cut-off level in patients with intermediate PSA values for the 
early detection of prostate cancer. Gan To Kagaku Ryoho 
2000;27 Suppl 2:514-22.
Shahab, et al.  PSA and PSAD cutoff points for indonesian men suspected for prostate cancer
30
PROSTATE INTERNATIONAL
20. Erdogan K, Gurdal M, Tekin A, Kirecci S, Sengor F. The ef-
fect of urethral catheterisation on serum prostate- specific 
antigen levels in male patients with acute urinary retention. 
Yonsei Med J 2003;44:676-8.
21. Chawla R, Abraham R, Arora U, Mammen K. Effect of urinary 
retention on the levels of prostate specific antigen (PSA) and 
prostatic acid phosphatase (PAP) in prostatic disease. Indian 
J Urol 2003;19:120-4.
22. Lipsky K, Schips L, Pummer K, Rehak P, Zigeuner R. Influ-
ence of indwelling transurethral catheters on PSA-levels in 
patients with benign prostatic hyperplasia [abstract]. Eur 
Urol Suppl 2005;4(3):106.
23. Onur R, Littrup PJ, Pontes JE, Bianco FJ Jr. Contemporary 
impact of transrectal ultrasound lesions for prostate cancer 
detection. J Urol 2004;172:512-4.
24. Gosselaar C, Roobol MJ, Roemeling S, Wolters T, van Leen-
ders GJ, Schroder FH. The value of an additional hypoechoic 
lesion-directed biopsy core for detecting prostate cancer. BJU 
Int 2008;101:685-90. 
25. Hofner T, Pfitzenmaier J, Alrabadi A, Pahernik S, Hadaschik 
B, Wagener N, et al. PSA density lower cutoff value as a tool to 
exclude pathologic upstaging in initially diagnosed unilateral 
prostate cancer: impact on hemiablative focal therapy. World 
J Urol 2012;30:91-5.
